IONIS PHARMACEUTICALS INC 8-K

What Happened

• On April 21, 2026, Ionis Pharmaceuticals announced additional positive results from the pivotal Phase 1–3 study of zilganersen in children and adults with Alexander disease (AxD). The 60-week randomized, double-blind treatment period included 53 participants aged 2–53 years.
• The study met its primary endpoint in patients aged ≥5 years: zilganersen 50 mg produced statistically significant and clinically meaningful stabilization of gait speed on the 10‑Meter Walk Test at Week 61 (least‑squares mean difference 33.3%, p = 0.041). In children 2–4 years, the Gross Motor Function Measure‑88 (GMFM‑88) favored zilganersen (LS mean difference 22.9 points, nominal p = 0.034). An exploratory analysis showed a 33.6% reduction in plasma GFAP at Week 61 versus control (nominal p = 0.003). Results were presented at the 2026 American Academy of Neurology annual meeting.

Key Details

• Trial size and ages: 53 people with AxD, aged 2–53, 60‑week double‑blind randomized period.
• Primary endpoint (≥5 years): 10MWT LS mean difference 33.3%, p = 0.041 at Week 61; zilganersen 50 mg.
• Younger children (2–4 years): GMFM‑88 LS mean difference 22.9 points (nominal p = 0.034; multiplicity not controlled).
• Biomarker and safety: plasma GFAP reduced 33.6% (nominal p = 0.003); most adverse events were mild/moderate; serious treatment‑emergent adverse events occurred in 37.5% of zilganersen (25 mg or 50 mg) vs. 47.1% pooled control.
• Regulatory status: Zilganersen is under FDA Priority Review with a PDUFA action date of September 22, 2026.

Why It Matters

• These pivotal results are material because they show a statistically significant benefit on the study’s primary motor endpoint and supportive signals across motor function, patient/clinician‑reported outcomes and a relevant biomarker (GFAP).
• For investors, the data feed directly into Ionis’s ongoing regulatory process (Priority Review/PDUFA date Sept 22, 2026) for an investigational therapy in a rare, progressive disease with no approved disease‑modifying treatments. The filing also reports an acceptable safety/tolerability profile in the trial population.